This study addresses this gap by analyzing National Cancer Database (NCDB) data to evaluate the comparative effectiveness of chemotherapy alone, Secondary analysis of GOG 258 suggests p53 status may be
GOG 258 Final Results: No Improvement in Survival by Adding Given the final results of GOG258, what regimen do you
GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer Chemotherapy plus radiation was not associated with The GOG-0213 Trial in Recurrent Ovarian Cancer
Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses the histogenesis of GOG-258 and PORTEC-3 Studies in Endometrial Cancer | OncLive The objective of this study was to examine the utilization of the GOG 258 arms-- (adjuvant chemotherapy (CT) vs chemoradiotherapy (CRT)-- for patients with
The purpose of the current trial (GOG 258) was to evaluate the use of concurrent tumor volume鈥揹irected external-beam radiation therapy and Off study utilization of an unpublished trial regimen: A real-world Bradley J. Monk, MD, FACS, FACOG; Thomas Herzog, MD; and Leslie M. Randall, MD, MAS, consider the goals of therapy in
Krishan Jethwa (@KrishanJethwa). 94 likes 5 replies. Secondary analysis of GOG 258 suggests p53 status may be predictive (Yes! I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained
馃尭Alasi pwidwngmwn jwngnao馃グ Alasiya ma ma labwkw馃 Dr. Rao on the Histogenesis of Endometrial Cancer
Management of Uterine cancer according to ESGO guidelines Listen to hear about GOG249, PORTEC3 and GOG258. *the note on immunotherapy at the end is not for adjuvant treatment! Beyond GOG258 and PORTEC3: A National Cancer Database
GOG 258: Adjuvant Chemotherapy plus Radiation for Locally The study is definitive evidence that says chemotherapy alone is enough. We don't need to radiate those patients.
Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer Dr Victoria Bae-Jump on Challenges in Treating Patients With Endometrial Cancer Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial Cancer
Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women High Risk Endometrial Cancer Adjuvant Therapy Trials
PORTEC 3 showed benefit for CTRT vs RT, while GOG 258 showed no difference in disease free survival between CT and CTRT. We aim to establish trends in Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Dr. Leath on Ongoing Trials for Endometrial Cancer
Adjuvant Chemotherapy plus Radiation for Locally Advanced KEY POINTS 路 NRG Oncology GOG-258 evaluated the benefit of chemoradiotherapy vs chemotherapy alone in patients with locally advanced endometrial
Dr. Levine Discusses a Combination Study in Endometrial Cancer Two studies that examined the role of chemoradiation in high-risk endometrial cancer patients include PORTEC-3 and GOG-258. PORTEC-3 was initiated to
However, patients in GOG 258 who received chemotherapy alone had an unacceptably high risk of developing locoregional recurrence (27% 5-year incidence combining Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses Dr. Klopp Discusses Chemoradiation in Endometrial Cancer
Trends in Management of Node Positive Endometrial Cancer after